初代细胞市场－全球产业规模、份额、趋势、机会、预测：按产品、来源、最终用户、地区和竞争对手划分，2021-2031年

全球原细胞市场预计将从 2025 年的 21.3 亿美元成长到 2031 年的 30.2 亿美元，复合年增长率为 5.99%。

该市场由直接从活体组织中分离的细胞组成，这些细胞保留了供体的生理特性，是体外研究中永生化细胞株的更优替代方案。该领域的成长主要受慢性病日益增多以及生物製药研究的扩展所驱动，后者需要精确的毒性和疗效筛检模型。根据美国製药製造商协会 (PhRMA) 发布的《2024 年报告》，全球有超过 8000 种药物处于临床开发阶段，如此庞大的研发管线直接推动了临床前检验中对原代细胞的需求。

儘管市场成长环境良好，但组织来源的伦理和物流复杂性仍构成重大挑战。取得高品质的人体组织需要严格遵守监管规定，且依赖有限的捐赠资源，这可能导致供应瓶颈，并限制特定细胞类型用于研究的取得。因此，取得必要的生物材料需要严格的采购流程，这构成了市场准入的一大障碍。

市场驱动因素

全球癌症和慢性疾病发生率的不断上升是推动市场发展的根本动力。研究人员被敦促优先使用初代细胞来模拟复杂的病理过程，因为与永生化细胞株相比，原代细胞具有更高的生理保真度。这些生物材料至关重要，尤其是在肿瘤学研究中，它们对于阐明肿瘤微环境和评估患者个体化的药物反应至关重要。根据美国癌症协会发布的《2024年癌症事实与数据》，预计光在美国，当年就将新增2,001,140例癌症病例。日益加重的疾病负担使得可预测的临床前模型变得特别重要，并直接增加了对用于药物发现和生物标记鑑定的健康组织和病变组织的需求。

同时，以细胞为基础的研究经费显着增加，从而加强了利用初代细胞进行高阶筛检所需的必要基础设施。这笔资金流入使生技公司能够扩大营运规模，并整合依赖这些供体来源细胞的复杂检测平台。正如再生医学联盟在其2024年1月发布的「产业趋势」简报中所指出的，2023年全球再生医学领域吸引了117亿美元的投资。这一强劲的资金势头与高效的监管审批相辅相成。美国食品药物管理局（FDA）在2023年核准了55种新疗法，这是其历史上单年核准数量第二高，进一步巩固了对初代细胞的依赖，从而最大限度地减少后期临床试验的失败率。

市场挑战

全球初代细胞市场的扩张受到获取人体组织相关的伦理和物流复杂性的显着限制。获得具有活性且高品质的细胞需要严格遵守法规结构和伦理知情同意程序，这导致采购时间延长。由于初代细胞必须直接从活体组织中分离，製造商严重依赖数量有限的合格供体，从而造成供应瓶颈，难以维持大规模生物製药计划所需的特定细胞类型的稳定库存。

这些短缺直接影响研发活动的扩充性。当某些细胞类型无法取得时，毒性测试和药物筛检计画就会延误，这必然会增加製药公司的营运成本。供体组织短缺仍然是影响材料供应的一个长期存在的问题。根据美国卫生资源和服务管理局 (HRSA) 的数据，到 2024 年，美国国家器官移植等待名单上的人数将超过 10.3 万人，凸显了器官和组织严重短缺的问题。人体组织供需之间的巨大差距极大地限制了可商业性生产的初代细胞数量。

市场趋势

在监管压力日益增加以及社会对符合伦理的研究模式的需求推动下，以人源取代动物实验的方法正在从根本上重塑全球初代细胞市场。这项转变优先考虑获取人源初代细胞，以取代毒理学和安全性评估中的动物源性基材，旨在提高其与人类健康结果的生物学相关性。这种伦理调整的基础是公民的实际参与，他们影响立法蓝图。根据善待动物组织（PETA）2025年4月发布的报告《欧盟分阶段废除动物实验》，欧盟委员会制定分阶段淘汰化学品安全评估中动物实验的蓝图，正是对一项获得超过120万个检验签名的欧洲公民倡议的直接回应。

同时，利用原代细胞建构的微生理系统正为供体特异性组织带来极具价值的应用，其发展历程也从简单的二维培养演变为复杂的器官模拟环境。这些先进的平台（晶片器官）高度依赖高品质的原代细胞来复製生理功能，从而解决了传统非临床试验中常见的转化差距问题。随着製药开发商寻求降低高失败率，这些系统的应用正在加速。根据《製药外包》（Pharmaceutical Outsourcing）2025年3月刊报道，约92%至96%成功通过动物试验的药物最终在人体临床试验中失败。这凸显了市场对这些以人为中心的初代细胞模型的迫切需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球初代细胞市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品分解（造血系统、皮肤细胞、肝细胞、消化器官系统、肺、肾、心臟、肌肉骨骼系统）
  • 依来源（人源初代细胞、动物源初代细胞）
  • 依最终用户（製药公司、生技公司、CROS、学术机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美初代细胞市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲初代细胞市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区初代细胞市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲初代细胞市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲初代细胞市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球初代细胞市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AllCells
• ZenBio Inc.
• PromoCell
• Thermo Fisher Scientific Inc.
• Cell Biologics Inc.
• STEMCELL Technologies Inc.
• Merck KGaA
• American Type Culture Collection（ATCC）

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Primary Cells Market is projected to expand from USD 2.13 Billion in 2025 to USD 3.02 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.99%. This market consists of cells isolated directly from living tissue that retain the physiological traits of the donor, offering a superior alternative to immortalized cell lines for in vitro studies. The sector's growth is largely fueled by the rising prevalence of chronic diseases and the expanding biopharmaceutical research landscape, which requires accurate models for toxicity and efficacy screening. As reported by the Pharmaceutical Research and Manufacturers of America in 2024, there were over 8,000 medicines in clinical development globally, creating an extensive pipeline that directly amplifies the demand for primary cells during preclinical validation phases.

Despite these favorable growth conditions, the market faces significant hurdles related to the ethical and logistical complexities of tissue sourcing. Securing high-quality human tissue demands strict regulatory compliance and relies on a finite pool of donors, resulting in supply bottlenecks that can restrict the accessibility of specific cell types for research applications. Consequently, obtaining the necessary biological materials involves navigating stringent procurement processes, which acts as a substantial impediment to market accessibility.

Market Driver

The rising global incidence of cancer and chronic diseases serves as a fundamental catalyst for the market, prompting researchers to prioritize primary cells for modeling complex pathologies with higher physiological fidelity than immortalized lines. These biological materials are essential for oncology studies, particularly in deciphering tumor microenvironments and evaluating patient-specific drug responses. According to the American Cancer Society's 'Cancer Facts & Figures 2024', it was projected that 2,001,140 new cancer cases would be diagnosed in the United States alone during the year. This increasing disease burden necessitates predictive preclinical models, directly intensifying the demand for both healthy and diseased primary tissue for drug discovery and biomarker identification.

Concurrently, a significant increase in financial support for cell-based research is strengthening the infrastructure required for advanced screening utilizing primary cells. Capital inflows allow biotechnology entities to scale operations and integrate sophisticated assay platforms that depend on these donor-derived cells for validity. As noted by the Alliance for Regenerative Medicine in their January 2024 'State of the Industry' briefing, the regenerative medicine sector attracted $11.7 billion in global investment throughout 2023. This financial momentum is matched by high regulatory productivity; the U.S. Food and Drug Administration approved 55 novel therapeutics in 2023, the second-highest annual total in its history, further solidifying the reliance on primary cells to minimize late-stage clinical attrition.

Market Challenge

The expansion of the global primary cells market is significantly constrained by the ethical and logistical complexities associated with sourcing human tissue. Obtaining viable, high-quality cells requires strict adherence to regulatory frameworks and ethical consent procedures, which often prolongs procurement timelines. Because primary cells must be isolated directly from living tissue, manufacturers depend heavily on a limited pool of suitable donors, creating unavoidable supply bottlenecks that make it difficult to maintain consistent inventories of specific cell types required for large-scale biopharmaceutical projects.

These shortages directly impact the scalability of research and development operations. When specific cell types are unavailable, toxicity testing and drug screening timelines are delayed, inevitably increasing operational costs for pharmaceutical companies. The scarcity of donor tissue remains a persistent issue affecting material availability; according to the Health Resources and Services Administration, over 103,000 people were on the national transplant waiting list in the United States in 2024, highlighting the critical shortage of organs and tissues. This widespread gap between the demand for human tissue and available supply severely limits the volume of primary cells that can be commercially produced.

Market Trends

The shift toward human-derived alternatives to animal testing is fundamentally restructuring the global primary cells market, driven by intensifying regulatory pressure and public demand for ethically sourced research models. This transition prioritizes the acquisition of human primary cells to replace animal-derived substrates in toxicology and safety assessments, ensuring greater biological relevance for human health outcomes. The momentum for this ethical realignment is evidenced by substantial civic engagement influencing legislative roadmaps; according to PETA's April 2025 report on phasing out animal testing in the EU, the European Commission's development of a roadmap to phase out animal testing in chemical safety assessments was directly responsive to a European Citizens' Initiative that secured over 1.2 million verified signatures.

Simultaneously, the development of microphysiological systems using primary cells is creating a critical high-value application for donor-specific tissues, moving beyond simple 2D cultures to complex, organ-mimicking environments. These advanced platforms, or organ-on-chips, rely heavily on high-quality primary cells to replicate physiological functions, offering a solution to the translational gap often seen in traditional preclinical studies. The adoption of these systems is accelerating as pharmaceutical developers seek to mitigate high attrition rates; according to Pharmaceutical Outsourcing in March 2025, approximately 92% to 96% of drugs that successfully pass animal testing subsequently fail in human clinical trials, underscoring the urgent market necessity for these human-centric primary cell models.

Key Market Players

• AllCells
• ZenBio Inc.
• PromoCell
• Thermo Fisher Scientific Inc.
• Cell Biologics Inc.
• STEMCELL Technologies Inc.
• Merck KGaA
• American Type Culture Collection (ATCC)

Report Scope

In this report, the Global Primary Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Primary Cells Market, By Product

• Hematopoietic
• Dermatocytes
• Hepatocytes
• Gastrointestinal
• Lung
• Renal
• Heart
• Musculoskeletal

Primary Cells Market, By Origin

• Human Primary Cells
• Animal Primary Cells

Primary Cells Market, By End user

• Pharma Biotech
• CROS
• Academia

Primary Cells Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Primary Cells Market.

Available Customizations:

Global Primary Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Primary Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal)
  • 5.2.2. By Origin (Human Primary Cells, Animal Primary Cells)
  • 5.2.3. By End user (Pharma Biotech, CROS, Academia)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Primary Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Origin
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Primary Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Origin
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Primary Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Origin
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Primary Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Origin
      • 6.3.3.2.3. By End user

7. Europe Primary Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Origin
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Primary Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Origin
      • 7.3.1.2.3. By End user
  • 7.3.2. France Primary Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Origin
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Primary Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Origin
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Primary Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Origin
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Primary Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Origin
      • 7.3.5.2.3. By End user

8. Asia Pacific Primary Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Origin
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Primary Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Origin
      • 8.3.1.2.3. By End user
  • 8.3.2. India Primary Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Origin
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Primary Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Origin
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Primary Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Origin
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Primary Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Origin
      • 8.3.5.2.3. By End user

9. Middle East & Africa Primary Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Origin
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Primary Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Origin
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Primary Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Origin
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Primary Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Origin
      • 9.3.3.2.3. By End user

10. South America Primary Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Origin
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Primary Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Origin
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Primary Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Origin
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Primary Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Origin
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Primary Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AllCells
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ZenBio Inc.
• 15.3. PromoCell
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. Cell Biologics Inc.
• 15.6. STEMCELL Technologies Inc.
• 15.7. Merck KGaA
• 15.8. American Type Culture Collection (ATCC)

16. Strategic Recommendations

17. About Us & Disclaimer